Fat Grafting in Reducing Recurrence in Patients With Healed Venous Ulcers A Prospective Randomised Clinical Pilot Study
NCT ID: NCT05239416
Last Updated: 2022-02-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
20 participants
INTERVENTIONAL
2022-02-28
2023-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Research of Prognostic Factors Associated With Healing of Venous Leg Ulcers
NCT01673412
Effect of rhGM-CSF on the Healing of Venous Leg Ulcers
NCT04823962
Lipofilling for Healing of Chronic Wounds
NCT05509673
Study Investigating the Safety and Efficacy of HP802-247 in the Treatment of Venous Leg Ulcers >12 cm2 to ≤ 36 cm2
NCT01737762
Evaluation of Safety and Activity of Celaderm in Healing Venous Leg Ulcers
NCT00399308
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This is a randomised, prospective, active-control pilot study to compare the effectiveness of fat grafting combined with compression therapy to compression therapy alone on reducing ulcer recurrence in patients with healed venous ulcers in a tertiary vascular care centre. This study will randomise 20 patients with previously healed venous ulcers in an equal ratio to one of two treatment arms. The intervention arm will be randomised to undergo fat grafting combined with compression therapy. The control arm will be offered compression therapy only. They will then be followed up in the outpatient clinic at 4 weeks, 8 weeks and 1 year.
Study setting:
Potential participants will be identified and screened at the vascular outpatient clinics within the Saolta group university hospitals, Ireland. Patients will receive the intervention in operating theatre in Roscommon University Hospital (RUH). Fat grafting will be performed under the supervision of a plastic surgeon. The coordinating centre will be the Department of Vascular and Endovascular Surgery, University College Hospital Galway (UCHG), and the School of Medicine at the National University of Ireland Galway (NUI Galway).
Study screening:
Patients with healed venous ulcers will be invited to join the study. Researchers will screen the patient for inclusion and exclusion criteria. Invited patients will be provided with a pre-designed information leaflet. This leaflet will be fully explained to the patient at the initial assessment. The study researchers will answer any questions about the study. Informed consent will be obtained from the patient on a formatted consent form. Patients will be given the freedom to give consent either on the same day or later.
Baseline visit:
Patients will undergo detailed clinical assessment by the researcher as part of the baseline evaluation. Recorded assessments will include:
* Demographics
* General clinical details (ABPI, comorbidities, medication history)
* Previous ulcer history (location, size, time since healing).
* Details of venous disease (previous deep vein thrombosis, previous venous interventions, CEAP classification)
* Assessment and recording skin thickness of the previously healed ulcer area using ultrasound.
* Quality of life and pain scale assessment scores
Sample size:
There are currently no previous studies from which we can withdraw a power calculation for this trial. Previous studies on the use of fat grafting have looked at fat grafting in pressure sores not venous ulcers. To our knowledge there are no studies that have used fat grafting in healed venous ulcers. As such this study is designed as a pilot study. The proposed sample size for this pilot study is 20 patients, being randomised to 10 patients in each arm.
Randomisation:
After meeting the inclusion criteria, screened patients will be randomised to one of two treatment arms. The intervention arm will receive fat grafting combined with compression therapy. The control arm will be offered compression therapy only. This is an intention to treat designed study, where patients are analysed as randomised. Each screened patient will be given a unique screening number.
Sequence generation:
Screened patients will be randomised in a 1:1 ratio of study intervention: control according to a randomisation scheme. The randomisation scheme will be produced using the PROC PLAN® procedure of the SAS® software package (version 9.2.2) using a simple randomisation strategy. The scheme will be concealed from all patients and study personnel until after database lock.
Allocation concealment:
Patients will be allocated to intervention via sequentially numbered opaque sealed envelopes, which will not deliver the randomised allocation except after registering the subject screening number. Each screened patient who is recruited to the trial will be given a unique patient trial number.
Blinding:
It will be impossible to blind the investigator and the patient due to the obvious difference in the surgical approach. Outcome assessors will be blinded. However, in the event of an adverse event outcome assessors will be unblinded.
Statistical analysis:
All data will be analysed according to the intention to treat principle. The comparison of the time to recurrence in the two arms will be performed by using Kaplan Meier survival curves and Log rank test. The outcome measures of recurrence rates and adverse events will be assessed using Chi square or Fisher's Exact, where appropriate. An exact 95% confidence interval will be applied for the difference between intervention groups. Skin thickness will be reported as change from baseline in millimetres. Recurrence rates will be correlated to change in skin thickness
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Fat grafting combined with compression therapy
Fat grafting + compression bandages/stockings
Fat grafting:
For the purposes of this study, the standard technique will be used for all patients
* General or local anaesthesia.
* Performed under the supervision of a plastic surgeon.
* Harvest site will be either abdomen or lower limb.
* After harvesting fat by liposuction, the lipoaspirate (which contains the ASCs) will be injected at the base of the healed venous ulcer within the same aseptic operative setting.
Compression therapy:
compression bandages / stockings as per routine practice
Fat grafting
Under general or local anaesthesia, fat will be harvested from either abdomen or lower limb. After harvesting the fat by liposuction, the lipoaspirate will be injected underneath the healed ulcer area under complete aseptic operative setting
Compression therapy only
Compression therapy:
compression bandages / stockings as per routine practice
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Fat grafting
Under general or local anaesthesia, fat will be harvested from either abdomen or lower limb. After harvesting the fat by liposuction, the lipoaspirate will be injected underneath the healed ulcer area under complete aseptic operative setting
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Able to provide written informed consent.
* Healed primary venous ulcers (C5 on CEAP classification) of 5cm or less for at least 1 month.
* Ankle-brachial pressure index (ABPI) of 0.8 or more.
Exclusion Criteria
* Evidence of deep venous occlusion
* Malignancy or immune-suppression
* Malnutrition
* Multi-organ failure
* Pregnancy
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National University of Ireland, Galway, Ireland
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Mohamed Elsharkawi
Mr
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mohamed Elsharkawi
Role: PRINCIPAL_INVESTIGATOR
University College Hospital Galway
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mohamed Elsharkawi
Galway, , Ireland
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
118/12
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.